University of Massachusetts Amherst

ScholarWorks@UMass Amherst
Masters Theses 1911 - February 2014
1983

A role for serotonin in the hypothalamic-pituitary-adrenal
response to insulin stress.
Rachel Yehuda
University of Massachusetts Amherst

Follow this and additional works at: https://scholarworks.umass.edu/theses

Yehuda, Rachel, "A role for serotonin in the hypothalamic-pituitary-adrenal response to insulin stress."
(1983). Masters Theses 1911 - February 2014. 2284.
https://doi.org/10.7275/7ja0-hy89

This thesis is brought to you for free and open access by ScholarWorks@UMass Amherst. It has been accepted for
inclusion in Masters Theses 1911 - February 2014 by an authorized administrator of ScholarWorks@UMass
Amherst. For more information, please contact scholarworks@library.umass.edu.

A ROLE FOR SEROTONIN IN THE HYP OTH ALAMI C-P I TUI TARY -ADRENAL
RESPONSE TO INSULIN STRESS

A Thesis Presented
By

RACHEL YEHUDA

Submitted to the Graduate School of the
University of Massachusetts in partial fulfillment
of the requirements for the degree of

MASTER OF SCIENCE
May

1983

Department of Psychology

A ROLE FOR SEROTONIN IN THE HYPOTHALAMIC-PITUITARY -ADRENAL
RESPONSE TO INSULIN STRESS

A Thesis Presented
By

RACHEL YEHUDA

Approved as to style and content by:

S.
&w*J
Jerrold
Meyer, ChairpeMon
S.

of Committee

Melinda A. Novak, Member

George N. Wade,

yt em ber

Royer Acting
dtment of Psycholo
M.

,

lrperson

DEDICATION

This is dedicated to all the tollbooth workers on the
Mass

Turnpike without whose tireless devotion, through snow, rain,
fog,
traffic, and the independent trucker's strike, this thesis would
not have been commuted.
Also, to my beloved husband Mitch, who was somewhat supportive.

ii

i

ACKNOWLEDGEMENT

I

am indebted to my adviser Dr. Jerrold

S.

Meyer for his

constant guidance and support, his inspiration and
instruction,
and his unlimited patience.
I

am also grateful to Dr. Melinda A. Novak and Dr. George

Wade for serving as my thesis committee and providing good
advice, insightful suggestions and encouragement.

A special note of thanks goes to my friends for their moral
support and good will, most notably, Hank Heller, who has made
many helpful comments concerning this work.
Thanks are also due to Christina Decoteau for helping with
the preparation of this manuscript.

iv

ABSTRACT
A Role for Serotonin in the Hypothalamic -Pituitary-Adrenal
Response to Insulin Stress
May

1983

Rachel Yehuda, B.A., Touro College
M.S., University of Massachusetts

Directed by:

Professor Jerrold

S.

Meyer

Controversy exists concerning the possible involvement of

serotonin in the pituitary-adrenocortical response to stress.

In

the present research, a variety of physiological and pharmacological

manipulations were used in male rats to study the role of this

neurotransmitter in the adrenocortical response to insulin- induced
hypoglycemia.

First,

the effect of insulin stress on hypothalamic

5-HT metabolism was examined, and an increased turnover was found
as determined by an enhanced accumulation of 5-HT following mono-

amine oxidase inhibition.

The corticos terone response to insulin was

potentiated by prior administration of L-tryptophan, and blocked by
pretreatment with valine, an amino acid that competes with tryptophan for transport across the blood-brain barrier.

Treatment with

the 5-HT receptor blocker methysergide, or serotonin depletion by

intraventricular injection of

5

,

7-dihydroxy tryptamine significantly

attenuated the insulin- induced rise in circulating corticosterone.
It therefore appears that the pituitary-adrenal response to insulin

is mediated at

least in part, by 5-HT, and may be dependent on

increased uptake of tryptophan by the brain.
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CHAPTER

I

INTRODUCTION

Although many neurotransmitters are thought to play a role in
regulating the hypothalamic-pituitary-adrenal (HP A) axis in response to stress, investigators to date cannot completely agree on
what these neurotransmitters are, and the relative contribution of
each.

There is even controversy concerning the excitatory or in-

hibitory actions of the

neurotransmitters which have been

suggested to regulate this endocrine system.

In order to under-

stand the controversies which have ensued over the past two decades

concerning the neural regulation of the hypothalamic-pituitary-

adrenocortical system, it is necessary to briefly review some of
the characteristics of this system as well as the limitations of
the methods and techniques which have been used to study it.

The HPA axis

.

The hypothalamus receives various neural inputs

which control the secretion of corticotropic releasing hormone
(CRH), a Al-amino acid peptide (Vale et al., 1981).

This peptide

is released from specialized CRH-containing neurons which have

been detected in the anterior parvocellular region of the para-

ventricular nucleus complex in the rat hypothalamus as well as in
the median eminence (Bloom et al., 1982).

1

CRH reaches the anterior

2

pituitary via the hypophyseal portal circulation, where it stimulates the synthesis and release of adrenocorticotropic hormone
(ACTH)

.

In response to ACTH, the adrenal glands produce and

release glucocorticoids (corticosteroids).
In addition to stress-induced hormone release, other aspects

of the HPA system involve the regulation of basal circadian CRH

release and feedback suppression of CRH.

The neural inputs which

regulate these different aspects of HPA hormone secretion are
thought to be at least partially independent of one another.

Evidence suggests that basal circadian periodicity involves reg-

ulation by the suprachiasmatic nucleus, whereas feedback regulation
occurs via limbic system inputs (for review, see Krieger, 1977).

While the following discussion will focus mainly on the reg-

ulation of the HPA stress-response, these other aspects of HPA
hormone secretion need to be mentioned because of their potential
effects on the corticosteroid response to stress.

For example,

stress induced hormone release may differ according to the relative

amounts of corticosteroids present in the circulation at the time
of stress exposure (Vernikos-Danellis & Heybach, 1980)

.

Adrenal

sensitivity to ACTH also varies in response to such factors as
time of day (Dallman et al., 1976).

Thus, although the central

mechanisms which regulate circadian rhythmicity may be distinct
from those regulating the stress response, stress-induced adreno-

cortical secretion may be affected by diurnal variation.

Addition-

ally, it is important to note that these characteristics may share

.

one or more neurotransmitters, and
as such may shed light on stress
induced HPA function.

Indeed, evidence has been accumulating
to

suggest the involvement of one particular
neurotransmitter in all

areas of HPA function.

This neurotransmitter is serotonin
(5-HT)

Techniques used to stud y serotonergic regulation
of HPA hormone
release.

A variety of techniques have attempted to
elucidate a

role for 5-HT in hypothalamic-pituitary-adrenocortical
functioning
in response to stress.
* in

These studies fall into four categories:

vitro studies of hypothalamic CRH secretion in response

to 5-HT and 5-HT altering drugs
*

studies on the effect of 5-HT and 5-HT altering drugs on

HPA hormone secretion in unstimulated animals
*

studies on the effect of 5-HT and 5-HT altering drugs

under conditions where the HPA system has been stimulated
*

studies on the ability of stress to affect brain 5-HT

metabolism.

In vitro studies of hypothalamic CRH secretion in response to 5-HT

and 5-HT altering drugs

.

A number of investigators have measured

CRH act ivity in isolated hypothalami of adrenalectomized rats in

response to various neurotransmitters and drugs.

In general these

studies have been consistent in obtaining evidence which supports
a

stimulatory role for 5-HT.

Jones, Hillhouse and Burden (1976)

and Buckingham and Hodges (1979) found that 5-HT could stimulate
CRH release in a dose-dependent manner.

This effect was

antagonized by the 5-HT receptor blocker methysergide.
In a more recent study Holmes et al.

(1982) have found that

5-HT induced CRH activity could be potentiated by
chlorimipramine
or d-fenfluramine, two drugs which are thought to
cause an in-

creased concentration of 5-HT in the synaptic cleft.

(The former

drug is a known 5-HT reuptake inhibitor, and the latter drug
is

presumably a 5-HT releasing drug.)

In addition, treatment with

5,7-dihydroxytryptamine (5,7-DHT), a 5-HT neurotoxin, enhanced
CRH secretion in response to 5-HT administration

—

an effect

which is probably due to increased sensitivity of 5-HT postsynaptic receptors following 5,7-DHT administration.

While a 5-HT stimulation can be clearly seen in these
studies, there is some dispute as to the relative importance of

other neurotransmitter systems which may or may not be influencing
5-HT induced CRH secretion.

For example in the aforementioned

study by Jones et al., 5-HT stimulated CRH release could be atten-

uated by two cholinergic antagonists, hexomethonium and atropine.
Jones et al. therefore concluded that while 5-HT acts to stimulate

hypothalamic CRH secretion, such stimulation may be mediated

through a cholinergic interneuron.

This conclusion is consistent

with the finding of Hillhouse, Burden and Jones (1974) that
acetylcholine (ACh) itself stimulates the release of CRH.

Buckingham and Hodges were able to replicate this latter finding,
however they were unable to block 5-HT induced CRH release with

anticholinergic drugs.

Thus, they concluded that cholinergic cells

A

may be involved in CRH regulation but not
necessarily in the
capacity of interneurons.
In the study of Buckingham and Hodges ACh
induced CRH release

was antagonized not only by anticholinergic drugs,
but by the

neurotransmitters norepinephrine (NE) and gamma-aminobutyric
acid
(GABA)

.

These studies taken together provide evidence for 5-HT

and other neurotransmitter receptors in the hypothalamus
which

regulate CRH release, and suggest, at least under the specified
in vitro conditions, that 5-HT functions to stimulate CRH

secretion.

Studies on the effect of 5-HT and 5-HT altering drugs on HP

hormone secretion in unstimulated animals
5-HT administration

.

.

The effect of intracranial injections

on pituitary-adrenal activity has been studied in several species.

Krieger and Krieger (1970) observed a stimulation of pituitary

adrenocortical activity with intraventricular injections of 5-HT
in cats.

In guinea pigs, 5-HT injections into several brain areas

elevated plasma 17-hydroxycorticosteroids in both intact animals
and in those which had received midbrain transections (Naumenko,
1968)

.

This latter result indicated that 5-HT induced HPA stim-

ulation does not involve ascending pathways below the level of the
transection.
In a subsequent study, the same investigator (Naumenko,

1969) showed that 5-HT injections into different brain regions

may cause differences in HPA functioning.

In this study, a rise

in plasma corticosteroids was seen in response
to 5-HT injections
to the ventral hippocampus, while 5-HT administered
to the dorsal

hippocampus produced a 20% decrease in plasma 17-hydroxycorticosteroids.

Similarly, an increase in corticosteroids was seen when

5-HT was injected into the septum while a decrease was seen
in
the amygdala.

The results of this study suggest that different

5-HT pathways may act in a different capacity to mediate pituitary-

adrenocortical activity.

This is consistent with the idea of

independent neural inputs regulating HP A activity.

Vermes and Telegdy (1972) showed that 5-HT intraventricular
injections had no effect on pituitary-adrenal activity in rats.
It is therefore difficult to draw firm conclusions from these

studies, however the majority are consistent with the in vitro

experiments which support a primary stimulatory role for 5-HT in

HPA hormone secretion.
Administration of 5-HT precursors

.

L-5-hydroxy tryptophan

(5-HTP) is the immediate precursor to 5-HT and has been used to

study the involvement of 5-HT in pituitary-adrenal functioning.
In rodents

doses of 50 mg/kg (Fuller, Snoddy

&

Molloy, 1976;

Meyer, Buckholtz & Boggan, 1978) to 100 mg/kg (Popova, Maslova

&

Naumenko, 1972) 5-HTP produced elevations in circulating corticosteroids.

This effect was potentiated by a monoamine oxidase (MAO)

inhibitor (a drug which prevents the degredation of 5-HT and

catecholamines into their precursors by the enzyme MAO) (Fuller
Clemens, 1981).

This suggests a hormone elevation due to 5-HT,

&
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but does not rule out the possibility of
an involvement of other

monoamines such as NE and dopamine (DA), since
MAO inhibition may
have an effect on the release of these
neurotransmitters.
Fluoxetine, a 5-HT reputake inhibitor significantly
poten-

tiated the 5-HTP induced rise in circulating
corticosterone
(Fuller, Snoddy, & Molloy, 1976).

This clearly suggests a hormone

elevation due to serotonergic activity.

Attempts have also been

made to attenuate the increase in corticosterone seen with
5-HTP.
Meyer, Buckholtz and Boggan (1978) found that metergoline and

cyproheptadine antagonized the effect of 5-HTP in mice.

Steiner

and Grahame-Smith (1979) found no effect with those particular 5-HT

receptor blockers in rats, but did see an antagonism of the 5-HTP
effect using mianserin, a less potent receptor blocker which may
be acting at a different 5-HT receptor site.

Meyer and co-workers

also found that the 5-HTP effect was significantly attenuated by

peripheral decarboxylase inhibitors in rats (submitted for publication) and mice (1978), but others have not been able to rep-

licate these findings (Fuller, 1981; Steiner
1979).

&

Grahame-Smith,

In general, the success of 5-HT agents in altering the

corticosteroid response to 5-HTP suggests a 5-HT involvement in

pituitary-adrenal hormone regulation.

One problem in using this

precursor, however, is that the enzyme which converts 5-HTP to
5-HT is nonspecific and is found in other neurons, particularly

catecholaminergic ones.

Therefore, administration of 5-HTP can

result in 5-HT production in brain areas that don't usually

8

contain 5-HT.

This means that corticosterone changes in
response

to 5-HTP do not necessarily reflect the normal
physiology of sero-

tonergic HPA regulation.
For this reason, some experimentors argue that it is
more

desirable to use the dietary precursor of 5-HT, tryptophan.
Studies of L-tryptophan administration in man have been somewhat

successful in demonstrating a role for 5-HT in HPA hormone reg-

ulation but the nature of this role remains obscure:
and

Yashimi

Imura, Nakai

(1973) demonstrated that tryptophan at a high

dose (150 mg/kg) increases pituitary-adrenal activity, while Woolf
and Lee (1977) showed that tryptophan produced a decrease in base-

line Cortisol levels at the low dose of 20 mg/kg.
In animals it has been necessary to give very high doses of

tryptophan to obtain a rise in corticosterone since only a small

percentage of peripherally injected tryptophan enters the brain
(Fuller, 1981).

However, investigators have not been able to po-

tentiate this response with fluoxetine or attentuate it with p-

chlorophenylalanine (PCPA)

,

a potent 5-HT depleter (Fuller, 1980).

Thus, it is unclear whether the effect of very high doses of

tryptophan in elevating circulating corticosteroids is serotonergically mediated.

It

is unfortunate that there are so many method-

ological limitations in using 5-HT precursors to ascertain the role
of 5-HT in HPA hormone regulation; other 5-HT pharmacological

manipulations which have been free from these particular problems
have been able to address this issue more clearly.

Effect of serotonergic drugs.

Quipazine, a direct receptor

stimulant caused dose-dependent increases
in circulating cor-

ticosterone in rats (Fuller, Snoddy

&

(Meyer, Buckholtz & Boggan, 1978).

This effect was antagonized

Clemens, 1978) and mice

by metergollne in rats (Fuller & Snoddy,
1979), but not in mice
(Meyer, Buckholtz

Boggan, 1978).

&

The quipazine induced rise in

corticosterone was still seen in rats pretreated with
5,7-DHT
(Fuller, 1981).

This result was expected, as quipazine acts on

post-synaptic 5-HT receptors.
The 5-HT releasers fenfluramine and p-chloramphetamine (PCA)

also increased levels of corticosteroids (Fuller

&

Snoddy, 1980).

The effect of PCA was prevented by PCPA pretreatment

fluoxetine (Fuller

&

Snoddy, 1980).

,

and also by

PCPA depletes neurons of 5-HT

making small amounts of this neurotransmitter available for
release.

Fluoxetine inhibited the uptake of PCA into serotonergic

neurons, making them unable to affect 5-HT release.

Fluoxetine also elevated levels of corticosterone (Fuller,
Snoddy & Molloy, 1976), presumably by maintaining elevated levels
of 5-HT in the synapse and causing increased stimulation of post-

synaptic neurons.

Despite the rise in corticosterone seen with serotonergic
agonists, antagonists such as receptor blockers, depleters and

neurotoxins have not been able to lower baseline corticosterone
levels.

They have only been able to in some cases antagonize the

elevation of corticosteroids in response to agonists.

In fact,

.

.
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Meyer et al.

(1978) have found that cyproheptadine
and metergoline

alone actually elevated corticosterone
levels in mice.
That 5-HT antagonists attenuate
corticosterone responses only
in a state of hormone elevation suggests
that the HPA system may

respond differently to neurotransmitters,
particularly 5-HT, in
different ways depending on the system's level
of excitation.

If

this is true, 5-HT may mediate hormone secretion
differently in

response to stress, or under conditions where the
pituitary-adreno-

cortical system is stimulated.

The next section will review the

pharmacological data on the effect of 5-HT in stimulated animals,
and will pay particular attention to its inconsistencies with
the
af orement ioned

Effect of 5-HT and 5-HT altering drugs under conditions where the

HPA system has been stimulated

.

The results of studies using

stressful manipulations or other situations in which baseline

pituitary-adrenal activity is elevated have been difficult to
interpret for several reasons.

The primary one seems to be the

lack of consistency between data obtained in human and animal
studies

Human studies

.

In general, human studies have been consis-

tent with each other, and with both the in vitro studies and

studies of unstimulated organisms.

In most cases, results have

confirmed a stimulatory role for 5-HT.

For example, the 5-HT

receptor blocker metergoline reduced increased ACTH levels seen
in response to insulin stress

(Cavagnini et al., 1976).

11

In other situations (which are not accurately considered

stress-induced) where the HPA system is stimulated, other 5-HT

antagonists have produced similar effects.
goline, methysergide (Cavagnini et al.

,

In addition to meter-

1975) and cyproheptadine

(Plonk & Feldman, 1976) were effective in lowering increased

ACTH levels following metyrapone treatment.

(Metyrapone is an

adrenocortical antagonist which interferes with the synthesis of
corticosteroids, and as such eliminates feedback inhibition of
corticost eroids on ACTH.

This drug is often used to determine

whether hypersecretion of corticosteroids is due to adrenal tumors
or pituitary malfunctions.)

Cyproheptadine was also effective in reducing symptoms of
two clinical endocrinopathies, Cushing's disease, which is char-

acterized by adrenocortical hypersecretion (Krieger, Amorosa

&

Linisk, 1975), and Nelson's syndrome, in which excessive ACTH

secretion occurs as a result of bilateral adrenalectomy treatment
in Cushing s patients (Krieger & Luria, 1976).
f

These studies are

consistent with the idea that the role of 5-HT in the adreno-

cortical response to stress is stimulatory.
Animal studies

.

Results obtained from animal studies have

not been consistent with the human data.

Some investigators have

reported inhibitory effects of 5-HT on the pituitary-adrenal

response to stress.

In rats, for example, the increase in cir-

culating ACTH levels produced by ether was blocked by pretreatment with tryptophan, and enhanced by PCPA (Vernikos-Danellis

&

12

Berger, 1973).

Intraventricular injection of 5-HT (while reported

by these investigators to have no effect on
baseline HPA secretion) prevented the corticosterone increase in
response to surgical

stress (Telegdy

&

Vermes, 1976).

Other investigators, however, have failed to alter the

adrenocortical response to stress using serotonergic drugs.

The

5-HT reuptake inhibitor fluoxetine did not influence plasma cor-

ticosterone levels following either swim stress or insulin stress
(Fuller & Snoddy, 1977).

PCPA had no effect on increased plasma

corticosterone levels seen with hypoxia (oxygen deprivation) or
hypercapnia (oxygen deprivation

4-

carbon dioxide administration)

(Marotta et al., 1976), while 5-HT depletion produced by the

neurotoxin 5,7-DHT or electrolytic lesions of the midbrain raphe
did not alter the ACTH response to ether (Karteszi, 1981).
It would be tempting at this point in the discussion to

simply conclude that 5-HT stimulates the pituitary-adrenal system
in animals at a baseline hormone level, and inhibits or has no

effect on HPA hormones in response to stress.

Unfortunately,

studies of the effect of 5-HT on animals in response to stress are

contradictory, since some studies fail to find any role for 5-HT.

Before accepting the aforementioned conclusion it is necessary to
further investigate the effect of 5-HT manipulations on pituitary-

adrenal hormones in response to stress.

With respect to the disparity between studies of stimulated
humans and animals it appears that 5-HT regulation may function

.
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in a different manner in man and
rodents.

Ordinarily, this would

be an acceptable conclusion, however,
we shall now look at studies
on the effect of stress on 5-HT
metabolism in animals which in-

dicate a role for 5-HT which is quite in
contradiction with the

pharmacological studies which have just been
discussed.
The effect of stress on 5-HT bra in metabolism

.

Investigators have

taken two basic approaches to measure the
effect of stress on

brain 5-HT.

One method, used particularly in the earlier studies,

has been to administer a stressor to an animal, and
then simply

measure the content of this neurotransmitter in either the
whole
brain or various parts of the brain.

In these studies, elevated

levels of 5-HT were seen as an indication of increased 5-HT
synthesis.

Many of these studies showed that stress had no

effect on 5-HT, and concluded, therefore, that this neurotrans-

mitter was not involved in the regulation of the stress response.
Some investigators, however did see increased concentrations of

5-HT with stress.

De Schaapdryver

,

Preziosi and Scapagnini (1969),

for example, observed a 10% increase in whole brain 5-HT (and a

simultaneous drop in NE and DA)
In 1966, a more sophisticated method of looking at 5-HT

metabolism was described by Tozer, Neff and Brodie (1966)

.

This

method is based on assuming a steady state kinetics of the 5-HT
system.

That is, the rate at which tryptophan and 5-HT are con-

verted to 5-HT is considered to be equal to the rate of conversion

14

of 5-HT to its metabolite 5-HIAA.

This situation is characterized

as an open system; under these conditions
the level of brain 5-HT

remains constant and the rate of formation
of 5-HT is equal to the
rate of turnover.

Investigators can estimate the rate of 5-HT

synthesis by pharmacologically preventing the
conversion of 5-HT
to its metabolite 5-HIAA and measuring the
(exponential) decline

of 5-HIAA.

By plotting the logarithms of 5-HIAA .concentrations
at

various time points and using the slope of the line to
determine a
rate constant, one could express the rate at which
5-HT has been

synthesized (i.e., turnover) from the product of the rate constant
of 5-HIAA decline and the normal 5-HIAA level.

Alternatively,

one can measure the accumulation of 5-HT after inhibiting the

formation of 5-HT to 5-HIAA (Neff

&

Tozer, 1968).

After such

treatment 5-HT will accumulate in the brain at a rate proportional
to its synthesis.

This method is based on assuming a lack of feed-

back inhibition on tryptophan hydroxylase by 5-HT.
Bliss, Thatcher and Ailion (1972) looked at several types of

stressors and their effect on 5-HT content and turnover.

There

was no change reported in 5-HT content with foot shock in mice or
rats, but increased 5-HT turnover was seen in whole brain.

The

lack of altered 5-HT content was interpreted by Bliss, Thatcher
and Ailion to mean that brain levels of 5-HT remain stable even

during increased 5-HT synthesis, a phenomenon which may explain
the failure of some investigators to observe changes in 5-HT content.

Increased 5-HT turnover was also seen during sleep

15

deprivation stress, swim stress, and
psychosocial stress, which
involved exposing rat colonies to different
strains of rats in
a noval environment.

Increased 5-HT turnover in response to
stress was also observed by several other investigators.

Increased rates of 5-HT

turnover during restraint stress have been
observed in whole brain
(Kenneth & Joseph, 1982), in the cerebral cortex
(Morgan, Rudeen
&

Pfeil, 1975) and in the hypothalamus (Mueller
et ai.

,

1976).

Food deprivation and novelty stress also increased
whole brain

turnover (Curzon, Joseph

&

Knott, 1972; Knott, Joseph & Curzon,

1973; Knott, Hutson & Curzon, 1977).

The different methodological approaches discussed earlier

which attempted to determine the role of 5-HT in stress met with
contradictory results.

This line of research is no exception.

While the above studies are clearly consistent with a stimulatory
role for 5-HT in pituitary-adrenocortical function in response to
stress in rats, other experiments have produced data leading to an

opposite conclusion.
Telegdy and Vermes (1976) tested many types of stressors for
their effect on 5-HT turnover in brain hypothalami.

Some stressors,

like cold stress, restraint or two minute exposure to ether caused

rapid changes in both corticosterone levels reaching a peak, and
5-HT levels reaching a maximum descent at 30 minutes.

By 90

minutes following stress onset, levels of 5-HT started to ascend,

ultimately overshooting baseline levels.

Other stressors such as

16

electric shock or surgical stress
produced corticosteroid responses

which remained high even 90 minutes
after the onset of stress, although levels of 5-HT, which were
initially decreased, returned to

normal by that time.

A third type of stressor, such as
formalin

stress, produced low hypothalamic
5-HT levels and high corticos-

terone concentrations which lasted beyond
90 minutes.

This study

suggests that the very nature of the stressor
may affect the involve
ment of 5-HT in hormone regulation.
The depletion of 5-HT seen when HPA hormone
levels are

elevated suggests an inhibitory role for 5-HT.

According to

Telegdy and Vermes, under normal conditions 5-HT
exerts an in-

hibition on the hypothalamus, causing low baseline
corticosterone
levels.

During stress, 5-HT is depleted, and inhibition is re-

moved, thus increasing corticosterone plasma concentrations.

The

model further proposes that the elevated levels of corticosterone

subsequently restore the depleted hypothalamic 5-HT.

When 5-HT

levels, and therefore, the inhibition due to 5-HT are restored,

corticosterone levels return to their low baseline levels.
further support to this theory, the authors administered

1

To lend

mg/kg

i.p. corticosterone to rats and found a rapid increase in 5-HT

concentrations in the hypothalamus, mesencephalon and amygdala.

Administration of 20 yg 5-HT intraventricularly diminished the
rise in plasma corticosterone seen in response to surgical stress.
It is difficult,

indeed, to account for the contradictory

results seen in these experiments.

What these inconsistencies
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suggest, however, is that determining a role for
5-HT is perhaps

more complicated than simply deciding between its
actions as an
inhibitory or an excitatory neurotransmitter in response
to
stress.

One approach to take in explaining some of the in-

consistencies is to point out that scientists have been at somewhat of a disadvantage in their studies since 5-HT pharmacology is
not as far advanced as the pharmacology of certain other trans-

mitters such as the catecholamines.
Part of the lack of knowledge regarding 5-HT pharmacology is

directly related to an incomplete understanding of 5-HT receptors.
The existence of multiple 5-HT receptors in brain was suggested
as early as 1967 by studies in the cerebral cortex, where micro-

iontophoretically applied 5-HT produced either excitation or inhibition in some neurons (Roberts

&

Straughan, 1967).

Recent

data suggests that there are at least three different types of
5-HT receptors in the brain (Aghajanian, 1981).

Two 5-HT recep-

tors are post-synaptic; one type is thought to be excitatory
(Type 2) while the other suppresses neuronal activity (Type 1).

Located presynaptically are 5-HT autoreceptors which mediate 5-HT
inhibition.

Different drugs may act selectively at these different

5-HT receptor sites, but these interactions are not fully understood.

In addition, it is not clear whether 5-HT receptor types

mediate different actions of 5-HT in response to stress.
It is also necessary to point out that the range of

methodological techniques which have been used in various studies

.
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has made it more difficult for
researchers to obtain similar
results.

For example, in turnover studies,
experimenters have

not consistently looked in the same

brain regions.

In pharma-

cological studies, investigators have not
always used the same
drugs to alter HPA hormone secretion.
ferent stressors have been used.

In stress studies, dif-

This latter factor may particu-

larly account for much of the variability in
the data since

different types of stressors influence 5-HT differently,
and 5-HT

may act in a different capacity in response to
different stressors.
Another important factor to consider is that many studies
have suggested an involvement of other neurotransmitters either

directly or indirectly by virtue of a failure of serotonergic

manipulations to influence pituitary-adrenal activity.

Given the

complexity of interaction between neurotransmitters, it is expected
that some contradictions will arise.

Certainly it is important to

consider how other neurotransmitters may affect HPA hormone secretion.

Some of the aforementioned studies have indicated a

cholinergic involvement in HPA regulation.

-

There has also been

increasing evidence for the involvement of catecholarainergic
systems

Interactions of catecholaminergic neurotransmitters

.

Administration

of the DA agonist pergolide, elevated serum corticosterone concen-

trations in rats (Fuller

&

Snoddy, 1981).

Such stimulation was

prevented by pretreatment with DA antagonists.

Intravenous
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administration of the DA precursor L-dopa
similarly elevated levels
of Cortisol in humans (Wilcox et
al., 1975).

On the other hand,

i.v. pulse injections of the DA
blocker haloperidol enhanced

resting plasma Cortisol levels (Balestreri,
Bertolini, and Castello,
1979), a result consistent with the effect
of L-dopa in atten-

uating the plasma Cortisol response to
insulin-induced hypoglycemia seen by the same investigators.

Although these latter

results suggest an inhibition by DA of
pituitary-adrenocortical

hormone secretion, the authors suggest that haloperidol
may be
acting on DA postsynaptic (self-inhibiting) neurons,
and therefore

may actually be increasing DA synthesis.

Thus, it is not completely

clear what the action of DA may be in CRH regulation.
Studies on the effect of NE have been somewhat less ambiguous
and have shown that NE acts to inhibit CRH-ACTH secretion.

For

example, large doses of NE have been found to prevent the increase
in ACTH normally seen in response to surgical stress (Van Loon
et al.,

1971).

NE antagonists such as reserpine, a NE depleter

(Scapagnini et al., 1972) and alpha -methyl-p-tyrosine, an NE

synthesis inhibitor (Van Loon et al., 1971) seem to enhance stressinduced ACTH secretion.

These are just a few studies which indicate an involvement of

catecholamines in HPA regulation of hormone secretion.
it

Here too,

is unclear to what extent and in what capacity, these neuro-

transmitters are acting.

In many studies, catecholamines exert

direct action on HPA hormone secretion, however, in addition to
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this direct effect, these neurotransmitters
may exert action on

5-HT which could directly affect 5-HT
regulation of HPA functioning

Scope and purpose.

Despite the fact that studies concerning
the

neural regulation of stress continue to
accumulate, there is no
clear picture of the factors which regulate
HPA hormone secretion
in response to stress.

Even the experimenters who have inves-

tigated a role for 5-HT in the regulation of this
axis are still
in debate over whether 5-HT acts to
stimulate or to suppress this

axis.

In view of the controversial results cited above,
the

following experiments were performed in an attempt to clarify
the
role of 5-HT in the pituitary-adrenal response to stress.

The

stress of insulin-induced hypoglycemia was chosen because this

stressor is easily quantified and manipulated, it represents a

physiological challenge to the organism, and the stress response
can (through measurements of blood glucose) be assessed indepen-

dently of pituitary-adrenal activity.

CHAPTER

II

METHODS AND MATERIALS

General methods

.

Two hundred twenty six adult male Wistar
rats

were purchased from Charles River or bred in
our laboratory.
Animals were housed singly in a colony room under
a 14:10 light-

dark cycle (lights on at 0600 hours) and were fed
Purina lab chow
and tap water ad libitum

The rats weighed 225-350 g at the time

.

of experimentation.

All experiments took place between 0800 and 1100 hours when

the serum corticosterone concentration is low in the normal

diurnal rhythm.

All animals were fasted approximately 16 hours

before receiving insulin or vehicle.

At the appropriate time

after drug administration, animals were quietly removed from the

colony room and killed by decapitation at intervals of at least
2

minutes.

ice.

Trunk bloods were collected and allowed to clot on

Bloods were then centrifuged and the sera aspirated and

frozen at -40°C for corticosterone determination by radioimmunoassay.

In some cases, serum glucose analyses or hypothalamic 5-HT

determinations were also performed.

Experiment I:

Characterization of the corticosterone and glucose

response to insulin stress

.

Dose-response and time-course studies

were carried out in order to determine the parameters of both the
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corticosterone response to insulin and
the corresponding glucose
levels.

In the dose-response study, fasted
rats were injected

subcutaneously (s.c.) with one of

5

doses of insulin (Squibb,

UAO) ranging from 0.125-.250 U/kg or
saline, and were killed 40

minutes later.
For the time-course study, fasted rats
were killed 0, 20,
40,

60, and 80 minutes after the s.c.

insulin or saline.

injection of .20 U/kg

In both cases, serum corticosterone and

glucose were analyzed.

Experimen t II:
turnover

.

The effect of insulin stress on hy pot halamic 5-HT

Changes in 5-HT turnover after insulin or saline were

measured in order to determine whether the metabolism of this

neurotransmitter is altered in response to stress.

Turnover was

measured by preventing the degradation of 5-HT into 5-HIAA and
allowing 5-HT to accumulate in the hypothalamus.

This method is

similar to that of Tozer and Neff (1968) and is based on assuming
a lack of feedback inhibition by 5-HT on tryptophan hydroxylase,

the enzyme which converts tryptophan to 5-HTP.
In this experiment, MAO was inactivated with pargyline.

Fasted animals were injected intraperitoneally (i.p.) with 75 mg/kg

pargyline (Sigma Chemical Co.) and then

5

minutes later either

killed immediately or injected with 0.20 U/kg insulin or saline.
The latter two groups were killed 45 minutes after pargyline

administration.

5-HT turnover was measured by the accumulation of
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5-HT as a result of the pargyline
treatment.

Hypothalamic 5-HT

concentrations were determined in all
animals by the method described below.

Experiment III:

The effec t of physiological serotonerg ic

manipulations on the corti c osterone response
to insulin

s tr PRfi

.

It was of interest to determine whether
the rise in corticos-

terone associated with insulin stress is
a result of increased

availability of the 5-HT precursor tryptophan to
the brain.

In

this study the normal plasma concentrations
of tryptophan and

another amimo acid, namely valine, were altered.

Valine is a

neutral amino acid that has previously been shown to
compete with
tryptophan for entrance across the blood-brain barrier (Pardridge,
1979)

.

The administration of tryptophan and valine are in a sense

physiological serotonergic manipulations because of their potential ability to alter the availability of tryptophan, and therefore, of 5-HT synthesis.
In the first part of this study, L-tryptophan (Sigma Chemical

Co.) was tested for its ability to potentiate the effect of a

submaximal dose of insulin on circulating corticosterone levels.
Fasted animals were pretreated s.c. with 200 mg/kg tryptophan
20 minutes before receiving 0.150 U/kg insulin or saline.

Next,

animals were pretreated s.c. with 200 mg/kg valine 20 minutes
before receiving 0.20 U/kg insulin or saline.

Blood samples were

obtained in the usual manner 40 minutes following insulin
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treatment

Experim ent IV:

The e ffect of pharmaco logic al
manipulations

corti costerone response to insulin
stress

.

onj^

Two pharmacological

manipulations were employed to investigate
the effect of 5-HT

antagonism on the corticosterone response
to insulin.

The first

study attempted to determine whether the
insulin -induced rise
in corticosterone could be attenuated
with a drug that blocks

serotonergic action.
5

mg/kg methysergide

Fasted animals were pretreated i.p. with
(Sandoz

,

Inc.) a serotonergic receptor

blocker, 1 hour before receiving 0.20 U/kg
insulin or saline.

Animals were killed AO minutes following this latter
injection.
Next, brain 5-HT was depleted using the potent 5-HT
neuro-

toxin 5,7-DHT (Sigma Chemical Co.).

5,7-DHT decreases brain

5-HT by about 70-80% when measured 8-12 days after administration

(Baumgarten et al., 1975).

Rats were anesthetized with Equithesin

(Jensen Salsber Laboratories), placed in a stereotaxic instrument,

and then injected intraventricularly with 150 yg of 5,7-DHT (free
base) in 20 yl of 0.1% ascorbic acid.

Control animals received

an equal volume of the ascorbic acid alone.

Because 5,7-DHT

can also produce a moderate depletion of brain NE, animals were

pretreated i.p. with 25 mg/kg desipramine (Merrel Dow Research)
45 minutes before drug or vehicle injections.

Desipramine is a

potent inhibitor of NE uptake, and therefore prevents 5,7-DHT
from entering noradrenergic neurons (Bjorklund, Baumgarten

&

.
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Rensch, 1975).

Ten days later, fasted animals
were killed 40

minutes following the injection of
0.20 U/kg insulin or saline.
Blood samples were collected for
subsequent corticosterone deter-

mination and hypothalami dissected and
assayed for their 5-HT
content

Serotonin determination.

Following decapitation, brains were re-

moved and hypothalami were rapidly dissected
over ice.

A rostral

coronal cut was made from the ventral side of
the brain at the
level of the suprachiasmatic nuclei, and a
caudal transection was

made immediately posterior to the mammillary
bodies at the level
of the interpeduncular fossa.

The hypothalamus was removed from

its lateral boundaries, the entorhinal cortex,
with two
cuts.

5

mm

A final horizontal cut separated the hypothalamus from the

overlying thalamus.

Each hypothalamus was weighed, and then

homogenized in a total volume of

deproteinize the tissue.

2

.

0 ml of ice-cold

.AN HCIO4 to

In addition, 50 yl of 10% disodium

ethylenediamine tetra-acetate (EDTA) was added to the HCIO4 to
chelate any contaminating heavy metals during homogenization, and
50 yl ascorbic acid was added to protect the 5-HT during extrac-

tion.

Samples were centrifuged at -5°C for 20 minutes at

30,000 x

g.

Supernatants were decanted and were then brought up

to a pH of 5.5-6.0 using KOH.

One drop of 0.04% bromphenol blue

in absolute ethanol was added to each tube to aid in the pH

adjustment.

Samples were recentrif uged for

5

minutes to remove

the KC10 precipitate.
4

Supernatants were decanted and brought
to

room temperature, and were applied to

3

x 20 mm columns of a weak

cation exchange resin (Bio-Rex
70, Bio-Rad Laboratories) which had
been cycled according to the manufacturer
and then equilibrated
in a 0.1M sodium phosphate buffer, pH
6.5, containing 0.1% di-

sodium EDTA (Barches, Erdelyi & Angwin,
1972).

The columns were

washed first with 1.5 ml 0.02 M phosphate
buffer, pH 6.5 containing 0.2% disodium EDTA, and then with 1.0
ml deionized water,
as described by Holman, Angwin and Barchas
(1970).

5-HT was

eluted with two 0.5 ml aliquots of 2.5 N HC1,
most of the 5-HT
being recovered in the first eluate.

Each 5-HT eluate was reacted

with o-pthalaldehyde (OPT, Sigma Co.) (Maikel

&

Miller, 1966)

which had been repurified in our laboratory according to Jacobowitz
and Richardson (1978).

Stock solutions of 0.5 mg/ml OPT were made

weekly and stored at 4°C.

On the day of each assay, a portion of

this solution was diluted 1:19 in concentrated HC1 to yield a

working acidified OPT reagent.

For the standards, a stock solution

of 5-HT creatinine sulfate (Regis Chemical Co.) corresponding to

1.0 mg/ml free 5-HT was made up in 0.01 N HC1 and stored at 4°C
for up to 1 month.

A standard curve was constructed for each assay

by diluting the stock 5-HT solution in 2.5 N HC1 to a final con-

centration of 900 ng/ml.

Appropriate volumes yielding 9-67.5 ng

5-HT were placed in assay tubes and were then reacted with the

acidified OPT reagent.

Samples and standards were heated at

100°C for 10 minutes, cooled to room temperature, and then read
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on a Perkin-Elmer #1000 Spectrof
luorometer at (uncorrected) ex-

citation and emission wavelengths
of 364 nm and 480 nm respectively.

Unknowns were calculated from the
standards using a

least squares linear regression.

Rad io immunoassay.

For
rur thp
~c serum
tne Hpt-prminaHA^
determination of
corticosterone,

each frozen serum sample was thawed
and diluted 1:99 in 0.65 M

sodium buffer, pH 8.0.

Samples were heated at 75°C for 30

minutes to denature transcortin, an endogenous
corticosterone
binding globulin, and were then allowed to
cool to room temperature
For the preparation of standards, unlabeled
corticosterone

(Steraloids, Inc.) was dissolved in absolute
ethanol, and appro-

priate volumes yielding 20, 50, 100, 200, 500
and 1000 pg

corticosterone were placed in clean assay tubes.

Standards were

then evaporated under N and redissolved in 50 ul borate
buffer.
2
The RIA utilized a

H-cort icosterone tracer (92.0 Ci/mmol,

New England Nuclear) and an anticorticosterone antiserum (B3-163,
Endocrine Sciences).

3

H-corticosterone was diluted in absolute

ethanol, stored at -10°C, and periodically repurified by Sephadex

LH-20 column chromotography (Murphy

&

Diez D'Aux, 1975).

The

anticorticosterone antiserum was found to cross-react 0.4% with
Cortisol (based on 100% reactivity with authentic corticosterone)
4.9% with deoxycorticosterone, 0.7% with progesterone, and less
than 0.1% with both testosterone and estradiol.

The tracer-

antiserum mixture was prepared in a sodium borate buffer containing
0.2% bovine serum albumin (Sigma Co.) and 0.05% bovine gamma
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globulin (BGG) (Sigma Co.).

BGG was added to increase the mass
of

precipitated protein in the ammonium
sulfate step described below.
Two hundred yl of the trace-ant
iserum mixture was reacted

with 50 ul aliquots of the heat-denatured
samples and standards
(in duplicate)

Each tube contained approximately
6000-7000 CPM

.

of

H-corticosterone and a final antiserum dilution
of 1:1500.

Tubes were incubated for

2

hours at room temperature, and were then

precipitated with 250 yl of saturated ammonium
sulfate.

Samples

were centrifuged for 10 minutes at 2,800 RPM (room
temperature),
and the supernatant containing the unbound corticosterone
was

decanted into a scintillation vial with 10 ml of a toluene-based
cocktail containing 4.0 g PPO and 0.1 g bis-MSB per

1.

The

pellets containing the precipitated antibody were discarded.
The unbound

H-corticosterone was allowed to partition into

the toluene phase overnight, and was read the next morning on a

Packard Tri-Carb #2425 scintillation counter.

jected to log-logit transformations.

The data were sub-

Unknowns were calculated

from the standards using least squares linear regression.

Each

assay included a quality control sample from a serum pool containing

approximately 32.5 yg of corticosterone per 100 ml.

The interassay

coefficient of variation calculated from these samples was 15.8%.

Glucose analysis

.

Serum glucose was analyzed by the glucose

oxidase method using kit //510A purchased from Sigma Co.

In this

procedure, a solution containing horseradish peroxidase and glucose

oxidase was added to diluted aliquots of serum.

Glucose oxidase
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was used to convert glucose to gluconic
acid, yielding hydrogen

peroxide as a by product.

The horseradish peroxidase and a

color reagent, o-dianisidine dihydrochloride
were then allowed
to react with the peroxide for 30
minutes at 37°C, yielding a

brown product, oxidized o-dianisidine.

The intensity of the

brown color as measured at 450 nm on a Bausch
and Lomb #88 spec-

trophotometer was proportional to the original
glucose concentration

A stock solution of 100 mg/dl beta-D-glucose in 0.1%
benzoic acid
was provided with the kit and stored at 4°C.

Standards of 50-

300 mg/dl were diluted in deionized water for use in the first of

these assays and standards of 50-100 mg/dl were used in each sub-

sequent assay.

Unknowns were calculated from the standards using

linear regression.

Data analysis

.

All data were subjected to analyses of variance

(ANOVA) followed by individual mean comparisons using Fischer's

Least Significant Difference Test (Kirk, 1968).

Data from the

turnover study were evaluated using a Student's t-test.

Results

occuring with a chance probability of less than .05 were considered

statistically significant.

CHAPTER III
RESULTS

Experiment

I

The effect of differing doses of insulin on
serum

.

corticosterone and glucose concentrations is shown in
Fig.

1.

Insulin significantly elevated serum corticosterone
(F 5 25 - 28.51)
and lowered glucose levels (F
5)2 4 " 4.49) in a dose-dependent

manner at all doses except the lowest one, .125 U/kg.
course of these responses to insulin is shown in Fig.

The time2.

Serum

corticosterone reached a maximum at 40 minutes and began to decrease by 60 minutes.

Post hoc testing revealed that all groups

of insulin treated animals were significantly higher than saline

controls (F
1>40

=-

64.04) except at the 20 minute time point.

Glucose levels in the insulin treated animals were found to be
different than saline controls at all times

Experiment II

.

(F^q

= 151.61;

Fig. 3).

The effect of insulin on hypothalamic 5-HT turnover

can be seen in Fig. 4.

The pargyline induced accumulation of 5-HT

40 minutes following insulin administration was significantly

higher than its accumulation following saline

(t

lg

= 2.67).

This

indicates an increased rate of hypothalamic 5-HT synthesis (turnover)
as a result of insulin stress.
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Dose

Fig.

of

Insulin

U/kg

Dose-dependent changes in serum corticosterone and
glucose concentrations following insulin.
Insulin was injected
s.c. at the doses indicated, 40 min before the animals were
decapitated.
Each value shown is the mean ± SEM for 5 rats
per group.
1.
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Time-course effect of insulin or serum glucose
in the same animals shown in Figure 2.
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amino acid concentrations pro-

duced substantial changes in the
corticosterone response to
insulin stress.

First, the effect of tryptophan
on a submaximal

dose of insulin was investigated.

An initial ANOVA performed on

the data yielded significant main
effects for both the treatment
(F

1>32 = 13.08) variables.

Rats given 0.150 U/kg of insulin

had higher overall corticosterone levels
than their saline-

injected counterparts, while tryptophan
pretreatment potentiated
the responses to both insulin and saline
(Fig. 5).
The effect of valine on the corticosterone
response to a

higher dose of insulin is illustrated in Fig.

6.

In this case,

an overall ANOVA on the results revealed a
significant inter-

action between treatment with insulin and pretreatment
with

valine (F
1>2Q =7.70).

It can be seen that

although 200 mg/kg

valine did not alter serum corticosterone in saline-injected
rats
the same dose almost completely prevented the stress-induced in-

crease in corticosterone observed following insulin.

Post hoc

testing confirmed that the valine-insulin animals were significantly different from the saline-insulin animals, but did not

differ from either control group.

These findings are consistent

with the idea that tryptophan availability plays an important rol
in the pituitary adrenal response to insulin-induced hypoglycemia

Experiment IV

.

Treatment with methysergide reduced levels of

circulating corticosterone in both insulin and saline treated
animals (F
=7.78).
1>2 7

As illustrated in Fig. 7, the effect of
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Fig.

Effect of tryptophan pretreatment on serum
corticosterone response to insulin stress. A dose of
0.15 U/kg insulin or saline was injected s.c. 40 min
before rats were killed and 20 min after the s.c. injection of 200 mg/kg L-tryptophan. Values represent the
mean ± SEM for 9 rats per group.
5.
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Fig.

Effect of valine pretreatment on serum corticosterone response to insulin stress. A dose of 0.20 U/kg
insulin or saline was injected s.c. 40 min before rats
were killed and 20 min after the s.c. injection of 200
mg/kg valine. Values represent the mean ± SEM for 6 rats
per group.
6.
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Effect of methysergide on the serum corticosterone response to insulin stress. Rats were pretreated with 5 mg/kg methysergide i.p. 1 h before receiving 0.20 U/kg insulin or saline and killed 40 min
later.
Values represent the mean ± SEM for 8 rats in
all groups except the methysergide-insulin group, in
which n = 7.
Fig.

7.
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methysergide was of greater magnitude in the
saline-treated controls..

It should be noted that these
controls have been subjected

to two mild stressors, namely i.p.

deprivation.

injection and 16 hour food

Thus, methysergide (at the present dose)
was capable

of inhibiting pituitary-adrenal responses
to stress, but a

smaller degree of inhibition was observed when
the stress was more
potent

Hypothalamic 5-HT content was depleted by an average
of 75%

when measured 10 days after treatment with 5,7-DHT
(mean hypothalamic 5-HT content

=0.19 yg/g tissue compared

in sham operated animals)

(Fig. 8).

to 0.76 yg/g

Analysis of the corticoster-

one data revealed a main effect for insulin treatment

(F,

=
9

36.25) and a significant interaction between insulin and 5,7-DHT
(F

l,20

=

1:L

-

62 )-

Post hoc testing showed that 5,7-DHT significantly

lowered the insulin-induced elevation of serum corticosterone
(Fig.

9).

Fig. 8.
Effect of 5,7-DHT on hypothalamic 5-HT
content 10 days after the intraventricular injection
150 yg 5,7-DHT in 0.1% ascorbic acid or vehicle alone
Values represent the mean ± SEM for 6 rats per group.
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Fig.

Effect of 5,7-DHT on the serum corticoster9.
oid response to insulin.
150 yg 5,7-DHT in 0.5% ascorbic
acid or vehicle alone was injected intraventricularly 45
min after pretreatment with 25 mg/kg desipramine.
0.20 U/kg insulin or saline were injected 10 days later
and the rats killed 40 min following this injection.
Values represent the mean ± SEM for 6 rats per group.
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CHAPTER

IV

DISCUSSION

The results of these studies support
the hypothesis that 5-HT

mediates, at least in part, the hypothalamic
-pituitary-adrenal

response to insulin stress.

This conclusion is based on the

increase in hypothalamic turnover observed as
a result of this
stress, and on the ability of the serotonergic
manipulations used
to appropriately alter these effects.

Tryptophan enhanced the pituitary-adrenal response to insulin while valine reduced it. Using these amino acids
as 5-HT

manipulations is based on the fact that tryptophan hydroxylase,
the rate-limiting enzyme in 5-HT synthesis is not saturated in

brain with its substrate, tryptophan (Friedman, Kappelman,
Kaufman, 1972).

&

Thus, 5-HT synthesis can be altered by either

increasing or decreasing the availability of tryptophan with respect to the enzyme.

One of the factors that influence

tryptophan availability to the brain is plasma concentrations of
large, neutral amino acids which compete with tryptophan for

transport across the blood-brain barrier (Pardridge, 1979).
Therefore, the amino acid tryptophan was administered so that its

concentration and subsequent entrance to the brain would increase.
Other animals received valine, which presumably ties up the sites
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on the carrier molecule and therefore
reduces the amount of tryp-

tophan entering the brain.

The increase in adrenocortical

activity seen with tryptophan, and the
decrease in response to

valine pretreatment suggest that the
functional response to insulin was partially related to tryptophan
availability.
In addition to plasma amino acid
concentrations, there are

other factors which affect tryptophan
availability to the brain.
One such factor appears to be the amount of
free vs. total

tryptophan in plasma (Knott

&

Curzon, 1972).

Tryptophan is the

only amino acid which is bound to albumin in plasma.

Normally,

about 80-90% of total tryptophan is bound while 10-20%
circulates
free (McMemory & Oncley, 1958).

Tryptophan shares its binding

site with nonesterified fatty acids (NEFA) which can displace

tryptophan and therefore alter the amount of free tryptophan cir-

culating in the blood.

If concentrations of NEFA increase, then

free tryptophan concentrations also increase.

Fasting, for

example, increases NEFA, thereby causing increased levels of free

tryptophan (Fernstrom, 1979).
It is unclear in which circumstances and to what extent the

concentration of free (as opposed to total) tryptophan plays
role in overall tryptophan availability to the brain.

a

For example,

Fernstrom and Wurtman (1971) have shown an increase in both 5-HT
turnover and brain tryptophan levels in response to insulin.
Insulin causes plasma NEFA to be taken up into various peripheral
tissues.

This liberates albumin binding sites in plasma, and
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therefore increases the proportion of
bound to free tryptophan.
The idea that free tryptophan
concentrations regulate tryptophan
availability under these conditions is
inconsistent with the

increase in brain tryptophan and 5-HT
seen by Fernstrom and
Wurtman, but this inconsistency can readily
be explained when we

consider two other factors.

First, insulin causes the peripheral

uptake of neutral amino acids as well as NEFA.
is bound to albumin,

it

Is not

Because tryptophan

particularly affected in this

I

manner by insulin, and therefore, the concentration
of total
tryptophan remains unchanged in comparison to the reduced
plasma

concentration of competing amino acids.

The second factor that

is important here is the discovery by Yuwiler et al.

(1977) that

tryptophan has a higher affinity for the brain capillary amino
acid transport carrier molecule than it does for albumin.

There-

fore, tryptophan, whether it is bound or free, can readily be

available for entrance to the brain.

In light of this,

it seems

that the most important factor regulating tryptophan availability

following insulin is the reduction of plasma amino acids which

compete with tryptophan for entrance into the brain.

The relative

concentrations of free vs. total tryptophan may also be important
factors, but they probably play a more significant role in

increasing brain tryptophan in the absence of reduced plasma amino
acid levels.

It is interesting to note that tryptophan also

increased the serum corticosterone concentrations in the noninsulin controls.

This increase may be due to the fasted state of
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the animals since previous studies (Meyer

&

Yehuda, unpublished

observations) have found no response to tryptophan
alone in

nonfasted animals.

The results of these experiments are con-

sistent with the idea that tryptophan availability
increases in

response to insulin due to the uptake of competing
amino acids
by peripheral tissues.

The resultant increase in brain trypto-

phan enhances 5-HT neurotransmission thereby activating

pituitary-adrenocortical secretion.
The pharmacological studies also support a role for 5-HT in
the adrenocortical response to stress.

Methysergide produced an

overall reduction in serum corticosterone concentration observed
following both the mild stress of fasting and saline injection
and the more severe stress of insulin-induced hypoglycemia.
Clearly, the effect of methysergide was more robust in reducing

corticosterone responses to the milder stress.

The inability of

methysergide to show a more substantial attenuation of the
response to insulin may be due in part to the great magnitude of
the corticosterone response to this stressor.

Alternatively, one could attribute the modest attenuation by

methysergide to the action of other neurotransmitters which may
be involved in the pituitary-adrenal response to insulin stress.

Although this possibility should not be ruled out, the other
studies reported above suggest a more significant role for 5-HT.
Thus, the weak effect of methysergide in contrast to the efficacy
of the other manipulations used here may be due to the particular
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pharmacological actions of this drug.
that methysergide blocks Type

2

but not Type

(Peroutka, Lebovitz & Snyder, 1981).

Introduction, Type
by 5-HT.

2

It is known,
1

for example,

5-HT receptors

As discussed in the

receptors mediate post-synaptic excitation

The partial inhibition of pituitary-adrenal functioning

by methysergide therefore suggests the possible involvement of
this specific receptor population.
The effect of methysergide on fasted, saline treated

animals is consistent with the idea of increased 5-HT synthesis
due to tryptophan availability.

In fasted animals there is an

increased concentration of free tryptophan due to the displace-

ment of tryptophan from plasma albumin binding sites by NEFA.
Since the plasma concentrations of related amino acids remain
unaltered, the increase in free tryptophan concentration becomes
an important factor in the availability of tryptophan for trans-

port into the brain and subsequent conversion to 5-HT.

Thus, the

effect of methysergide on serum corticosterone following fasting
and saline administration suggests that 5-HT mediates the

pituitary-adrenal response to this stressor as well.
It was important that the insulin treated animals have

comparable blood glucose levels to ensure a consistent

corticosterone response to the treatment.

Thus, it was necessary

to also impose this mild stress of fasting in the control group.

Because of this, the corticosterone levels in the control

animals do not represent baseline values, and therefore it is
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difficult to interpret the effects of pharmacological
manipulations that altered serum corticosterone
concentrations in this
group.

In an ideal situation, these drugs should
additionally

be tested on nonfasted subjects to discern
whether they would

also affect baseline levels in unstressed animals.

Treatment with 5,7-DHT significantly reduced the pituitary-

adrenal response to insulin, despite causing slightly increased
levels of circulating corticosterone in the saline-treated controls.
This latter result could be due to a nonspecific malaise or

weight loss produced by 5,7-DHT rather than its direct anti-

serotonergic activity in pituitary-adrenal functioning.

The

effectiveness of 5,7-DHT in lowering corticosterone responses to
insulin stress suggests that this process is centrally mediated.
The specific pathways involved in stimulating pituitary-adrenal

function in response to insulin stress, however are not yet
known.

The dorsal and medial raphe nuclei which are rich in

5-HT containing cell bodies have been shown to ascend to the

hypothalamus and therefore, are likely candidates for mediating
5-HT induced changes in CRH secretion.

General evidence for an

involvement of extrahypothalamic pathways is provided in a study
by Karteszi et al.

(1982) who reported that anterolateral

deaf ferentat ion of the hypothalamus greatly reduced the

corticosterone rise seen in response to insulin.

In contrast,

however, Aizawa, Yasuda and Greer (1981) have shown that com-

plete hypothalamic isolation did not prevent the corticosterone
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response to insulin.

The latter finding would be more
consistent

with a possible involvement of serotonergic
neurons within the
hypothalamus itself (Kent

&

Sladek, 1981).

Evidence for the

existence of 5-HT nerve terminals in the
hypothalamus which
stimulates CRH release have already been clearly
demonstrated
in the in vitro studies mentioned in the
Introduction.
it

Therefore,

is possible that these recently discovered
5-HT neurons within

the hypothalamus may act to mediate pituitary-adrenal
activity.

More studies will be needed to resolve this issue.
Although questions still remain the present research demonstrates a serotonergic mediation of the pituitary-adrenal

response to insulin stress which most likely depends on increased

tryptophan availability.

Other studies have similarly shown a

correlation between pituitary-adrenal stimulation and increased
brain tryptophan in response to immobilization stress (Curzon,

Joseph
1981)

Knott, 1973; Mueller et al.

&

.

,

1976; Kenneth & Joseph,

These studies showed comparable endocrine responses to

tryptophan administration and immobilization, and in one case

demonstrated that valine pretreatment reduced both the brain
tryptophan and adrenocortical effects following immobilization
(Kenneth

&

Joseph, 1981).

In other experiments, restraint stress

(Knott, Joseph & Curzon, 1973) and novelty stress (Knott, Hutson
& Curzon,

1977) were associated with increased plasma levels of

NEFA, suggesting that the increase in brain tryptophan seen in

response to these stressors may reflect an increased availability

of free tryptophan.

Thus, changes in brain 5-HT mediated

altered tryptophan availability may be
important in the

pituitary-adrenal response to a variety of
stressors.
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